UT Health San Antonio | The University of Texas Health Science Center at San Antonio
Category ID
51

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

<p>ERX-41, developed by UT Health San Antonio scientists, exploits a previously unrecognized weakness in breast cancer and other solid tumors. Media contact: Will Sansom, 210-567-2579, Sansom@uthscsa.edu SAN ANTONIO (June 2, 2022) – A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer [&hellip;]</p>

Share This Story

Faculty surgeon addresses Washington briefing, helps to guide regional trauma response

<p>&nbsp; UT Health San Antonio is an integral partner in the trauma network of San Antonio and South Texas – a national model that involves the military, the Level 1 Trauma Center at University Hospital, trauma faculty of the Joe R. and Teresa Lozano Long School of Medicine, regional hospitals and many other collaborators. Because [&hellip;]</p>

Share This Story

In Memoriam: William W. Dodge, DDS, former dean of UT Health San Antonio School of Dentistry

<p>Oversaw completion of Center for Oral Health Care &amp; Research Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO – William W. Dodge, DDS, former dean of the UT Health San Antonio School of Dentistry who oversaw completion of the state-of-the-art Center for Oral Health Care &amp; Research (COHCR) has died after an illness. Dr. Dodge served [&hellip;]</p>

Share This Story

Oral pill improves care of patients with bone marrow cancer: Study

<p>Results of MOMENTUM myelofibrosis clinical trial presented at ASCO 2022 Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu CHICAGO AND SAN ANTONIO (June 7, 2022) — Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, [&hellip;]</p>

Share This Story

Rapamycin increases Alzheimer’s-associated plaques in mice, study finds

<p>The research also reveals a novel way to decrease the plaques. This is a potential drug target. Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (June 7, 2022) — Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have found that oral administration of rapamycin to an Alzheimer’s [&hellip;]</p>

Share This Story

$10 million from Bexar County to assist School of Public Health development

<p>UT Health San Antonio, UTSA collaborate to reduce health disparities, train public health professionals Contact: Will Sansom, UT Health San Antonio, 210-567-2579, sansom@uthscsa.edu Joe Izbrand, UTSA, 210-458-8754, joe.izbrand@utsa.edu SAN ANTONIO (June 9, 2022) — Bexar County Commissioners Court gave preliminary approval June 7 to award $10 million to UT Health San Antonio and The University [&hellip;]</p>

Share This Story

Mays Cancer Center receives grants, continued support from American Cancer Society

<p>Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (June 13, 2022) – In late April, American Cancer Society (ACS) awarded the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, two check donations in the amounts of $480,000 for an institutional research grant and $65,000 for cancer support grants. Both checks were [&hellip;]</p>

Share This Story

Long School of Medicine’s first Nasta Symposium to feature discussion on infertility and reproductive concerns

<p>Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (June 14, 2022) – UT Health San Antonio’s Long School of Medicine Department of Obstetrics and Gynecology welcomes researchers, faculty, staff, residents, students, alumni and community providers to attend its inaugural event, the Dr. Armando Nasta Symposium on Gynecologic Innovation, on Friday, June 17. “There is extensive ongoing [&hellip;]</p>

Share This Story

Novel brain injury treatment tested in 1st human subject

<p>Drug conceived at UT Health San Antonio was safe, effective in animal studies Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO, TEXAS, AND GROTON, CONN. (Wednesday, June 15, 2022) — An experimental brain injury medication conceived in laboratories at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was tested Tuesday, [&hellip;]</p>

Share This Story

Pheo Para Alliance recognizes UT Health San Antonio as rare disease Center of Excellence

<p>Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 15, 2022) — Pheo Para Alliance, a patient advocacy organization dedicated to supporting those with pheochromocytoma (pheo) and paraganglioma (para), a rare neuroendocrine tumor, has designated The University of Texas Health Science Center at San Antonio (UT Health San Antonio) as a Pheo Para Center of Excellence. The [&hellip;]</p>

Share This Story

Subscribe to News Releases